Key result
Dexmedetomidine-remifentanil provides deeper sedation, lower pain scores, and ~93% fewer desaturation events than midazolam-remifentanil.
Why the study?
Does dexmedetomidine-remifentanil improve sedation and analgesia compared with midazolam-remifentanil in patients undergoing catheter ablation of atrial fibrillation?
Population
90 patients undergoing catheter ablation of atrial fibrillation (A-fib)
Comparison
Dexmedetomidine 0.2-0.7 µg/kg/h after a loading… vs Intermittent midazolam boluses combined with…
Design
RCT, randomized
Follow-up
during catheter ablation procedure
Authors
Loading...
Supports dexmedetomidine-remifentanil for AF ablation sedation; confirms RCT superiority over midazolam-remifentanil.
RCT (n=90)
randomized
Does dexmedetomidine-remifentanil improve sedation and analgesia compared with midazolam-remifentanil in patients undergoing catheter ablation of atrial fibrillation?
p-value: p=<0.001
Dexmedetomidine combined with low-dose remifentanil provides superior sedation, better analgesia, and less respiratory depression than midazolam with remifentanil during atrial fibrillation ablation.
Cho et al. (2013) conducted an RCT in Atrial fibrillation (n=90). Dexmedetomidine-remifentanil vs. Midazolam-remifentanil (midazolam 1-2 mg boluses with remifentanil 3.6-7.2 µg/kg/h) was evaluated on Sedation level assessed by Ramsay sedation and bispectral index scores (p=<0.001). Dexmedetomidine-remifentanil provided deeper sedation (P<0.001), fewer desaturation events (1 vs 15; P<0.001), and lower pain scores (0.95 vs 1.72; P=0.021) compared with midazolam-remifentanil.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: